THERAVANCE, GSK BEGIN ASTHMA CLINICAL PROGRAM

Theravance and GlaxoSmithKline (GSK) have enrolled the first patient in a Phase IIb clinical program with the investigational long-acting beta agonist (LABA) compound, 159797 ('797), in patients with mild-to-moderate asthma.

The companies will develop a once-a-day inhaled combination medicine comprised of a LABA and a corticosteroid. This step is part of the next phase in the collaboration, which will determine the LABA to take into the combination clinical trials program in patients.